US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Innoviva, Inc.

News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva to Participate in the UBS Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva to Participate in the BofA Securities Health Care Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
News headline image
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023
From Innoviva, Inc.
Via Business Wire